PTX 2.44% 4.2¢ prescient therapeutics limited

Ann: AGM Presentation, page-4

  1. 114 Posts.
    lightbulb Created with Sketch. 34
    Totally agree malmanu, considering ovarian & AML trials have been given the green light to proceed with slight change in protocol, one would think similar logic will apply with the phase 2 breast trial. With all that is going on in current ptx200 trials plus kicking off ptx100 in heamotology niche, I'm anticipating an SP re-rate to Edison valuation of 0.29 + is very likely in 2018! See you at the AGM...
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.